Spanish Group for Cancer Immuno-Biotherapies (GÉTICA) – 12th Forum on Translational Immunology and Immunotherapy of Cancer (FIT Cancer 12) 2026 (Videos)

Advanced Cancer Immunotherapy, Translational Oncology, Tumor Immunology, Biomarkers & Radio-Immunotherapy Updates

Stay at the forefront of modern cancer treatment with the Spanish Group for Cancer Immuno-Biotherapies (GÉTICA) – 12th Forum on Translational Immunology and Immunotherapy of Cancer (FIT Cancer 12) 2026, an advanced educational program dedicated to the latest breakthroughs in tumor immunology, translational oncology, and precision cancer immunotherapy.

Held March 5–6, 2026, at Hotel ILUNION Málaga in Málaga, Spain, this internationally recognized scientific forum brings together leading oncologists, immunologists, radiation oncologists, and translational researchers to bridge the gap between laboratory discoveries and clinical cancer care. Through expert lectures, multidisciplinary discussions, and cutting-edge scientific presentations, participants explore emerging biomarkers, cellular therapies, radio-immunotherapy, immune-related adverse events, and innovative treatment strategies across multiple solid tumors.

Designed to translate rapidly evolving immunologic discoveries into practical clinical applications, FIT Cancer 12 provides clinicians and researchers with evidence-based insights that support precision oncology and personalized cancer treatment.

Product Details

• Course: Spanish Group for Cancer Immuno-Biotherapies (GÉTICA) – 12th Forum on Translational Immunology and Immunotherapy of Cancer (FIT Cancer 12) 2026
• Organizer: Spanish Group for Cancer Immuno-Biotherapies (GÉTICA)
• Conference Dates: March 5–6, 2026
• Location: Hotel ILUNION Málaga, Málaga, Spain
• Format: Videos
• Language: English
• Educational Level: Advanced
• Learning Format: Scientific Lectures, Translational Research Updates, Clinical Case Discussions, Expert Panel Sessions

Course Overview

Cancer immunotherapy continues to transform oncology by enabling highly personalized treatments that harness the immune system to recognize and eliminate malignant cells. Rapid advances in tumor biology, immune checkpoint inhibitors, cellular therapies, biomarkers, and combination treatment strategies have created new opportunities while also introducing increasingly complex clinical decision-making.

The FIT Cancer 12 Forum 2026 delivers an in-depth review of translational cancer immunology, emphasizing the integration of basic immunologic science with real-world oncology practice. International experts present current research on innate and adaptive immunity, antigen presentation, cytokine biology, tumor microenvironment, predictive biomarkers, radio-immunotherapy, immune-mediated toxicities, and novel cellular therapies.

Participants gain valuable insights into emerging therapeutic approaches across gastrointestinal, bladder, gynecologic, head and neck, and other solid malignancies while strengthening their understanding of precision immuno-oncology.

What You’ll Learn

After completing this course, participants will be able to:

• Understand the immunologic mechanisms underlying cancer development and immunotherapy.
• Analyze innate and adaptive immune responses involved in tumor recognition and elimination.
• Evaluate the influence of cytokines and the tumor microenvironment on cancer progression and treatment response.
• Apply current principles of cellular immunotherapy and radio-immunobiology in modern oncology.
• Develop strategies for managing immune-related adverse events, including immunotherapy rechallenge after severe toxicity.
• Integrate biomarkers and precision medicine approaches into immunotherapy selection.
• Review the latest advances in radio-immunotherapy and multidisciplinary treatment strategies across multiple cancer types.

Comprehensive Topics Covered

Tumor Immunology

Develop a strong understanding of cancer immunology.

Topics include:

• Tumor immunology
• Cancer immunity
• Innate immunity
• Adaptive immunity
• Immune surveillance
• Immune escape
• Cancer immunobiology

Faculty review the biological foundations driving modern immunotherapy.

Antigen Presentation & Immune Activation

Strengthen knowledge of immune recognition.

Topics include:

• Antigen presentation
• Dendritic cells
• T-cell activation
• Major Histocompatibility Complex (MHC)
• Immune signaling
• Co-stimulation
• Tumor antigens

Cytokines & Tumor Microenvironment

Explore the biology of cancer progression.

Topics include:

• Cytokines
• Tumor microenvironment
• Immune regulation
• Inflammation
• Immunosuppression
• Stromal interactions
• Tumor progression

Cancer Immunotherapy

Review modern immunotherapeutic strategies.

Topics include:

• Immune checkpoint inhibitors
• Immunotherapy
• PD-1 inhibitors
• PD-L1 inhibitors
• CTLA-4 inhibitors
• Combination immunotherapy
• Precision oncology

Cellular Therapies

Learn the future of immune-based cancer treatment.

Topics include:

• Cell therapy
• Adoptive cell therapy
• Cellular immunotherapy
• Engineered immune cells
• Translational medicine
• Personalized therapy
• Emerging treatments

Radio-Immunotherapy

Integrate radiation and immunology.

Topics include:

• Radio-immunotherapy
• Radio-immunobiology
• Combination therapy
• Radiation oncology
• Immunomodulation
• Treatment sequencing
• Multimodal therapy

Biomarkers & Precision Oncology

Improve individualized treatment selection.

Topics include:

• Predictive biomarkers
• Molecular biomarkers
• Precision medicine
• Personalized oncology
• Biomarker-driven therapy
• Response prediction
• Translational biomarkers

Immune-Related Adverse Events

Optimize immunotherapy safety.

Topics include:

• Immune-mediated toxicity
• Immune-related adverse events (irAEs)
• Toxicity management
• Immunotherapy rechallenge
• Clinical decision-making
• Patient monitoring
• Supportive care

Gastrointestinal Oncology

Review advances in GI cancer immunotherapy.

Topics include:

• Gastrointestinal cancers
• Colorectal cancer
• Gastric cancer
• Hepatobiliary malignancies
• Immunotherapy
• Biomarkers
• Combination treatment

Bladder Cancer

Understand evolving immunotherapy approaches.

Topics include:

• Urothelial carcinoma
• Bladder cancer
• Immune checkpoint inhibitors
• Precision treatment
• Translational oncology
• Clinical advances
• Personalized therapy

Gynecologic Oncology

Strengthen multidisciplinary cancer care.

Topics include:

• Ovarian cancer
• Cervical cancer
• Endometrial cancer
• Gynecologic malignancies
• Immunotherapy
• Biomarker testing
• Precision medicine

Head & Neck Oncology

Review current immunotherapy advances.

Topics include:

• Head and neck cancer
• Squamous cell carcinoma
• Immunotherapy
• Radiation therapy
• Biomarkers
• Multidisciplinary care
• Translational oncology

Learning Objectives

Upon completion of this educational activity, participants will be able to:

• Understand the fundamental principles of tumor immunology, including innate immunity, adaptive immunity, antigen presentation, and immune activation.
• Analyze the role of cytokines and the tumor microenvironment in cancer progression and therapeutic response.
• Evaluate current and emerging cellular therapies and radio-immunobiology approaches in cancer treatment.
• Apply evidence-based clinical decision-making when considering immunotherapy rechallenge following Grade 3 immune-mediated toxicities.
• Assess emerging biomarkers and precision medicine strategies for patient selection.
• Integrate the latest advances in radio-immunotherapy for gastrointestinal, bladder, gynecologic, and head and neck cancers into multidisciplinary treatment planning.

Educational Highlights

• Cancer Immunotherapy
• Tumor Immunology
• Translational Oncology
• Precision Oncology
• Immune Checkpoint Inhibitors
• Tumor Microenvironment
• Cytokines
• Antigen Presentation
• Cellular Therapy
• Radio-Immunotherapy
• Biomarkers
• Personalized Medicine
• Gastrointestinal Oncology
• Bladder Cancer
• Gynecologic Oncology
• Head & Neck Oncology
• Immune-Related Adverse Events
• Clinical Oncology
• Translational Research
• Continuing Medical Education (CME)

Why This Course Stands Out

The GÉTICA FIT Cancer 12 – Translational Immunology and Immunotherapy of Cancer 2026 forum provides an exceptional blend of basic immunology, translational research, and clinical oncology. Rather than focusing solely on approved therapies, the program explores the biological mechanisms driving treatment response, biomarker development, immune modulation, and future therapeutic innovations. This multidisciplinary approach equips clinicians and researchers with the knowledge needed to integrate emerging immunotherapy strategies into precision cancer care.

Target Audience

This educational activity is ideal for:

• Medical Oncologists
• Radiation Oncologists
• Immunologists
• Urologists
• Gynecologic Oncologists
• Gastroenterologists
• Oncology Fellows
• Radiation Oncology Fellows
• Clinical Researchers
• Translational Scientists
• Pathologists
• Residents (MIR)
• Healthcare Professionals involved in cancer immunotherapy and translational oncology

Why Choose This Course?

Whether you specialize in medical oncology, radiation oncology, immunology, gastrointestinal oncology, gynecologic oncology, or translational cancer research, the Spanish Group for Cancer Immuno-Biotherapies (GÉTICA) – 12th Forum on Translational Immunology and Immunotherapy of Cancer (FIT Cancer 12) 2026 delivers one of the most comprehensive updates available in modern immuno-oncology. Through expert-led lectures, cutting-edge translational research, multidisciplinary discussions, and evidence-based clinical insights, participants gain practical knowledge to improve patient selection, optimize immunotherapy strategies, manage treatment-related toxicities, and advance precision cancer care.

Topics

Educational Session I: Principles of Tumor Immunology and Immunotherapy

• Innate immune response

• Adaptive immune response and antigen presentation

• Cytokines and the tumor microenvironment

• Principles of cell therapy

• Introduction to radioimmunobiology

Educational Session II: Applying Concepts Through Clinical Cases (GÉTICA–SEOM + MIR Session)

• Rechallenge with immunotherapy after grade 3 immune-mediated toxicity: clinical experience and case discussions

Scientific Symposium GÉTICA – Session 1: Radio-Immunotherapy

• Oligoprogression in the immunotherapy era: turning radiotherapy into a partner

• Epigenetics meets radio-immunotherapy: biomarkers and future directions

• Integrating radiotherapy and immune modulation: emerging strategies and translational perspectives in head and neck cancer

Scientific Symposium GÉTICA – Session 2: Immunotherapy Advances with Clinical Focus

• What is new in bladder cancer?

• What is new in gynecological cancer?

• What is new in gastrointestinal cancer?

Core Thematic Areas for Research and Communications

• Cell therapies

• New immunotherapy strategies for cancer treatment

• Biomarkers of response or toxicity to immunotherapy

• Integration of immunotherapies into multimodal treatments

• Mechanisms of response/resistance to immunotherapy